An Updated Individual-Patient-Data Systematic Review and Meta-Analysis of Reported DOCK8 Deficiency Cases (2017–2026): Genotype, Phenotype, Malignancy, Infection Spectrum, and Transplant Outcomes
Immuno · 06.08.2026 · 6 (3) · 52
DOI: 10.3390/immuno6030052 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Immuno, online erschienen am 06.08.2026. Verfasst von Raghad Saeed Asiri und 5 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dedicator of cytokinesis 8 (DOCK8) deficiency is an autosomal-recessive combined immunodeficiency marked by severe cutaneous viral infections, atopy with elevated IgE, malignancy, and early mortality without hematopoietic stem-cell transplantation (HSCT). Foundational syntheses predate the current transplant era and biologic therapy.
Objective
It aims to provide an updated individual-patient-data (IPD) synthesis of DOCK8 deficiency cases reported from 2017 to 2026.
Methods
Following PRISMA 2020 and PRISMA-IPD guidance, we searched PubMed/MEDLINE (with full Boolean strings provided for Embase, Scopus, Web of Science and Cochrane CENTRAL) for reports with extractable individual data on confirmed DOCK8 deficiency. Two-stage screening, Murad-2018 risk-of-bias assessment, random-effects Freeman–Tukey pooled proportions (with a random-intercept logistic model as a sensitivity analysis), and reconstructed Kaplan–Meier analyses were performed.
Results
Of 360 records, 56 full texts were assessed, and 41 studies were included; 29 provided individual data for 64 patients from 22 countries, and 12 contributed aggregate data. Sixty-three potentially eligible reports were paywalled and could not be retrieved, and non-English reports were excluded, introducing possible retrieval and language bias. Consanguinity was reported in 40/43 (93%); the genotype spectrum was dominated by large deletions and splice/intronic variants. Eczema (72%), cutaneous viral infection (80%) and bacterial infection (64%) predominated. The pooled proportion alive at last reported follow-up was 87.3% (95% CI 81.1–92.6); this is a cross-sectional proportion over variable follow-up and is not a long-term survival estimate, as reconstructed age-specific Kaplan–Meier survival fell to approximately 53% by age 20 (exploratory analysis). Pooled malignancy prevalence was 10.6% (95% CI 3.4–20.7; I2 = 66%), and pooled post-HSCT survival was 86.3% (95% CI 79.0–92.5).
Conclusions
Contemporary reports reaffirm the severe infectious and malignant burden of DOCK8 deficiency and support HSCT as definitive therapy, alongside emerging biologic (dupilumab, siltuximab) and gene-directed strategies. Findings are constrained by reporting, retrieval and language bias and by reconstructed IPD; completion of the planned multi-database searches and independent second-reviewer verification are ongoing to finalise the evidence base.
Zitieren
APA
Asiri, R. S., Amer, K. A., Al-Jahash, N., Alhudaithi, F., Alqahtani, R. A., & Alali, A. S. (2026). An Updated Individual-Patient-Data Systematic Review and Meta-Analysis of Reported DOCK8 Deficiency Cases (2017–2026): Genotype, Phenotype, Malignancy, Infection Spectrum, and Transplant Outcomes. Immuno, 6(3), 52. https://doi.org/10.3390/immuno6030052
Vancouver
Asiri RS, Amer KA, Al-Jahash N, Alhudaithi F, Alqahtani RA, Alali AS. An Updated Individual-Patient-Data Systematic Review and Meta-Analysis of Reported DOCK8 Deficiency Cases (2017–2026): Genotype, Phenotype, Malignancy, Infection Spectrum, and Transplant Outcomes. Immuno. 2026;6(3):52. doi:10.3390/immuno6030052
BibTeX
@article{Asiri2026,
author = {Asiri, Raghad Saeed and Amer, Khaled Abdulwahab and Al-Jahash, Najla and Alhudaithi, Faisal and Alqahtani, Rawan Abdullah and Alali, Amjad Saad},
title = {An Updated Individual-Patient-Data Systematic Review and Meta-Analysis of Reported DOCK8 Deficiency Cases (2017–2026): Genotype, Phenotype, Malignancy, Infection Spectrum, and Transplant Outcomes},
journal = {Immuno},
year = {2026},
volume = {6},
number = {3},
pages = {52},
doi = {10.3390/immuno6030052}
}
EUVIMED